📊 CNSP Key Takeaways
Investment Thesis
CNS Pharmaceuticals is a pre-revenue clinical-stage biotech company with severe profitability challenges and rapidly depleting cash resources. The company is burning approximately $10.8M annually in operating cash flow with no revenue generation, creating an unsustainable financial trajectory that threatens operational continuity within approximately 12 months at current burn rates.
CNSP Strengths
- Strong liquidity position with $9.9M cash representing 83% of total assets
- Zero long-term debt providing financial flexibility for future capital raises
- Moderate insider activity suggesting management confidence, though this is insufficient to offset fundamental concerns
CNSP Risks
- Complete absence of revenue with negative operating income of -$10.0M indicates failed commercialization efforts
- Unsustainable cash burn rate of -$10.8M annually will deplete cash reserves in approximately 12 months without external funding
- Severely negative returns on equity (-99.8%) and assets (-83.4%) demonstrate value destruction and poor capital allocation
- Clinical-stage biotech model with apparent failures in drug development or market adoption
- Diluted EPS of -$25.60 indicates aggressive shareholder dilution and capital inefficiency
Key Metrics to Watch
- Quarterly operating cash burn rate and cash runway remaining
- Progress on clinical trial milestones or regulatory approvals for pipeline candidates
- Revenue recognition from any commercialized products and gross margins
- Debt financing or capital raise activities that could extend runway or signal desperation
CNSP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.81x current ratio provides a solid financial cushion.
CNSP Profitability Ratios
CNSP vs Healthcare Sector
How CNS Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CNSP Balance Sheet & Liquidity
CNSP 5-Year Financial Trend
5-Year Trend Summary: CNS Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-12,509.11 indicates the company is currently unprofitable.
CNSP Growth Metrics (YoY)
CNSP Capital Allocation
CNSP SEC Filings
Access official SEC EDGAR filings for CNS Pharmaceuticals, Inc. (CIK: 0001729427)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNSP
What is the AI rating for CNSP?
CNS Pharmaceuticals, Inc. (CNSP) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNSP's key strengths?
Strong liquidity position with $9.9M cash representing 83% of total assets. Zero long-term debt providing financial flexibility for future capital raises.
What are the risks of investing in CNSP?
Complete absence of revenue with negative operating income of -$10.0M indicates failed commercialization efforts. Unsustainable cash burn rate of -$10.8M annually will deplete cash reserves in approximately 12 months without external funding.
What is CNSP's revenue and growth?
CNS Pharmaceuticals, Inc. reported revenue of N/A.
Does CNSP pay dividends?
CNS Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CNSP SEC filings?
Official SEC filings for CNS Pharmaceuticals, Inc. (CIK: 0001729427) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNSP's EPS?
CNS Pharmaceuticals, Inc. has a diluted EPS of $-25.60.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.